Novartis AG — Director's Dealing 2019

Feb 14, 2019

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: Intellia Therapeutics, Inc. (NTLA)
CIK: 0001652130
Period of Report: 2018-12-31

Reporting Person: Novartis Institutes for BioMedical Research, Inc. (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-05-16	Common Stock	J	25074	—	Acquired	4302147	Direct
2018-06-18	Common Stock	J	25074	—	Acquired	4327221	Direct
2018-07-16	Common Stock	J	25074	—	Acquired	4352295	Direct

Footnotes

F1: Pro rata distribution from Atlas Venture Fund IX, L.P., of which Novartis Institutes for BioMedical Research, Inc. ("NIBRI") is a limited partner.

F2: The shares are held directly by NIBRI. NIBRI is an indirect wholly-owned subsidiary of Novartis AG.